Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments

P. Zarzosa, N. Navarro, I. Giralt, C. Molist, A. Almazán-Moga, I. Vidal, A. Soriano, M. F. Segura, R. Hladun, A. Villanueva, S. Gallego, J. Roma*

*Corresponding author for this work

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

The use of preclinical models is essential in translational cancer research and especially important in pediatric cancer given the low incidence of each particular type of cancer. Cell line cultures have led to significant advances in cancer biology. However, cell lines have adapted to growth in artificial culture conditions, thereby undergoing genetic and phenotypic changes which may hinder the translational application. Tumor grafts developed in mice from patient tumor tissues, generally known as patient-derived xenografts (PDXs), are interesting alternative approaches to reproducing the biology of the original tumor. This review is focused on highlighting the interest of PDX models in pediatric cancer research and supporting strategies of personalized medicine. This review provides: (1) a description of the background of PDX in cancer, (2) the particular case of PDX in pediatric cancer, (3) how PDX can improve personalized medicine strategies, (4) new methods to increase engraftment, and, finally, (5) concluding remarks.

Original languageAmerican English
Pages (from-to)44-50
Number of pages7
JournalClinical and Translational Oncology
Volume19
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Animal models
  • PDX
  • Pediatric cancer
  • Personalized medicine
  • Solid tumors
  • Xenograft

Fingerprint Dive into the research topics of 'Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments'. Together they form a unique fingerprint.

Cite this